Court Place Advisors LLC Buys 2,807 Shares of Pfizer Inc. (NYSE:PFE)

Court Place Advisors LLC raised its position in shares of Pfizer Inc. (NYSE:PFE) by 9.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,754 shares of the biopharmaceutical company’s stock after acquiring an additional 2,807 shares during the period. Court Place Advisors LLC’s holdings in Pfizer were worth $919,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. Olistico Wealth LLC bought a new stake in shares of Pfizer in the second quarter valued at approximately $25,000. MFA Wealth Advisors LLC acquired a new stake in Pfizer in the 2nd quarter worth $29,000. Quarry LP bought a new position in shares of Pfizer during the 2nd quarter worth about $31,000. Trivant Custom Portfolio Group LLC raised its position in shares of Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 600 shares during the last quarter. Finally, Financial Connections Group Inc. bought a new stake in shares of Pfizer in the second quarter valued at about $34,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.1 %

NYSE:PFE traded up $0.04 during trading hours on Friday, hitting $28.68. The stock had a trading volume of 2,073,833 shares, compared to its average volume of 36,733,469. The business’s 50 day moving average is $29.07 and its 200-day moving average is $28.48. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. The company has a market cap of $162.52 billion, a price-to-earnings ratio of -62.28, a P/E/G ratio of 1.01 and a beta of 0.67. Pfizer Inc. has a one year low of $25.20 and a one year high of $31.54.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The business had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.67 EPS. Sell-side analysts anticipate that Pfizer Inc. will post 2.67 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 5.86%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is presently -365.21%.

Analyst Ratings Changes

Several equities analysts have commented on PFE shares. Wells Fargo & Company upped their price target on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Wednesday. Barclays lifted their price target on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. UBS Group increased their price objective on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Finally, Sanford C. Bernstein began coverage on shares of Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price on the stock. Eight investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $33.58.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.